

# **A new family of substituted steroidal BINOL-type ligands†**

Matthias F. Schneider,\* Michael Harre and Christian Pieper

*Process Research*, *Schering AG*-*Berlin*, *Mu¨llerstraße* 170–178, *D*-13342 *Berlin*, *Germany* Received 18 September 2002; accepted 23 September 2002

**Abstract—**The short and high yielding synthesis of a new family of substituted bissteroidal BINOL-type ligands employing the bisketone derivatives **Rax-**, **Sax-3** as the centre point of a 'chemical modular construction system' is reported. © 2002 Elsevier Science Ltd. All rights reserved.

## **1. Introduction**

 $BINOL<sup>1</sup>$  and  $BINAP<sub>z</sub><sup>2</sup>$  which have been employed in numerous catalytic and stoichiometric asymmetric reactions, have attracted great attention over the last several years as chiral auxiliaries and ligands with  $C_2$ -symmetry. Nevertheless there are at least two drawbacks for these compounds. The enantiomers of BINOL and/or of BINAP have to be separated by (i) transforming the racemic compounds into diastereomeric derivatives; (ii) separation of these derivatives; and (iii) retransformation into BINOL or BINAP. There are still reactions where BINOL or BINAP give only unsatisfactory results concerning the degree of enantioselection.

Therefore we have developed approaches towards a 13,14-*trans* (steroid nomenclature) configured bis-

steroidal phosphine<sup>3</sup> starting from equilenine and recently towards the 13,14-*cis* configured phosphine **4**<sup>4</sup> using estrone as relatively cheap starting material. We have employed these phoshines as chiral ligands in ruthenium based asymmetric hydrogenation cata $lvs$ ts.<sup>3,4</sup>

Even having accomplished the second synthesis of steroidal BINAP-type ligands (**Rax-**, **Sax-4**), we still saw room for improvement due to some difficulties we had encountered during our synthesis. The chemistry from **1** to the diastereomeric mixture of **2** proceeded uneventful, but we were by no means able to separate the deoxygenated ligands  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -2 by column chromatography on a preparative scale. Therefore we had to go via the bisketone derivatives  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ , 3 which we were able to separate via a preparative HPLC even on a kilogram scale.



*Keywords*: steroids; polycyclic aromatic compounds; naphthalenes; biaryls.

<sup>\*</sup> Corresponding author. Tel.: +49-(0)30-468-17190; fax: +49-(0)30-468-97190; e-mail: [matthias.schneider@schering.de](mailto:matthias.schneider@schering.de)

<sup>†</sup> Presented partly at ISHC 12, Stockholm, 27th August–1st September, 2000.

<sup>0040-4039</sup>/02/\$ - see front matter © 2002 Elsevier Science Ltd. All rights reserved. PII: S0040-4039(02)02154-8

Our new goals were (i) to generate a new family of substituted BINOL-like structures which could also be of interest as potential ligands; and (ii) to discover a synthetic route making the BINOL-type ligands  $\mathbf{R}_{ax}$ -, **S<sub>ax</sub>-2** available in its diastereopure forms.

#### **2. Results and discussion**

The starting point of our investigation was the bisketone derivatives **Rax-**, **Sax-3** (Scheme 1).

As we had envisioned, we were able to use  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -3 as the centre of a 'chemical modular construction system' to obtain a new family of differently substituted steroidal BINOL-type structures. The reduction of **3** using NaBH<sub>4</sub> gave rise to the tetraols  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -5 in quantitative yield.5 The hydrazone derivatives **Rax-**, **Sax-** $\vec{6}$  and  $\vec{R}_{ax}$ ,  $\vec{S}_{ax}$ -7 were obtained in 100% and 98% yield, respectively, by simply refluxing **3** with 4.2 equiv. of the necessary hydrazine derivative in EtOH.6 The employment of an excess of ethyleneglycol and of triethyl orthoformate in toluene using catalytic amounts of *p*-toluenesulfonic acid furnished the desired bisketals



**Scheme 1.** *Reagents and conditions*: (a) NaBH4, MeOH/THF 1:1, quant.; (b) *p*-toluenesulfonylhydrazine, EtOH, quant.; (c) hydrazine hydrate, EtOH, 98%; (d) 11 equiv. triethyl orthoformate, 0.1 equiv. PTSA, ethyleneglycol/toluene 1/6; 92%; (e) ethane dithiole,  $BF_3Et_2O$ ,  $CH_2Cl_2$ , quant.; (f) 4-pyridylethylmercaptan, excess  $BF_3Et_2O$ ,  $CH_2Cl_2/dichloroethane$  1/1, 18%  $S_{ax}$ -19.



**Scheme 2.** *Reagents and conditions*: (a) excess Raney-nickel, THF/EtOH 1:4,  $95\%$   $\mathbb{R}_{ax}$ -2/91%  $\mathbb{S}_{ax}$ -2; (b) Tf<sub>2</sub>O, NEt<sub>3</sub>, toluene; 100% **Rax-11**/85% **Sax-11**.

 $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -8 in very good yield (92%).<sup>7</sup> The bisthioketals  $\mathbf{R}_{\text{av}}$ ,  $\mathbf{S}_{\text{av}}$ -9 were available via Lewis acid (BF<sub>3</sub>·Et<sub>2</sub>O) mediated ketalisation with ethane dithiole.8 This reaction was scaled up to 500 g batch sizes without decreasing yields, which were quantitative. As a last example the thioenolether  $S_{ax}$ -10 was synthesized by treating **Sax-3** with an excess of 4-pyridylethylmercaptan and  $BF<sub>3</sub>Et<sub>2</sub>O$  at 50°C.<sup>8</sup> The yield of  $S<sub>ax</sub>$ -19 is only moderate up to now (18%), but nevertheless this compound could possibly exhibit interesting properties against metals (e.g. Cu) (Scheme 1).

Having in hand the bisthioketals  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -9, we were now able to obtain the desired compounds  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -2 in its enantiopure forms in only one additional step. Treatment of **Rax-**, **Sax-9** with an excess (15-fold) Raney-Nickel furnished **Rax-2** and **Sax-2** in 95 and 91% yield, respectively, as crystalline compounds after workup.8,9 Again the batch sizes have been scaled up to 700 g of starting materials **Rax-**, **Sax-9** without decreasing yields. In addition, this achievement leads the way towards an easier and cheaper way of synthesizing the bistriflates  $\mathbf{R}_{av}$ ,  $\mathbf{S}_{av}$ -11, which are the final intermediates in the synthesis of  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -4.<sup>4</sup> Our original route also started with the bisketone derivatives  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -3 which were transformed into the corresponding tetratriflates (excess  $Tf_2O$ ) first and then the enol triflates in position 17 (steroid nomenclature) were reduced using hydrogen and PtO<sub>2</sub> as catalyst to obtain  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -11. This procedure was not very reliable and in addition is very costly regarding scale-up. In contrast, reaction of **Rax-**, **Sax-2** with triethylamine and triflic acid anhydride in toluene at 0°C, coupled with easy scale-up, gave rise to  $\mathbf{R}_{ax}$ -11 in excellent yield (100%) and  $\mathbf{S}_{ax}$ -11 in good yield  $(85\%)$ <sup>2,3</sup>. The difference in yield is probably due to different solubilities of the *R*- versus the *S*-compounds influencing the work-up as well as the purification of **2** and **11** (Scheme 2).

### **3. Conclusion**

In conclusion, we have reached all our goals by creating a new family of bissteroidal BINOL-type ligands with the bisketone derivatives  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -3 as centre point thereby affording the ligands  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -2 in its diastereopure forms. In addition a more (cost) efficient way of synthesizing the bistriflates  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -11 has been developed.

The bisketone derivatives  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -3 have already been used as chiral ligands in the addition of diethyl zinc to aldehydes by Dimitrov et al.<sup>10</sup> In addition phosphate derivatives of  $\mathbf{R}_{ax}$ ,  $\mathbf{S}_{ax}$ -2 have been employed successfully as ligands for enantioselective 1,3-dipolar cycloaddition of carbonyl ylides by Hodgson et al.<sup>11</sup> Currently the chiral ligands described therein are tested in different asymmetric reactions. The results will be published in due course.

#### **Acknowledgements**

We thank T. Hilsmann, M. Stoppa, T. Schadendorf and J. Santos for experimental assistance.

#### **References**

- 1. (a) For a review, see: Rosoni, C.; Franzini, L.; Raffaelli, A.; Salvadori, P. *Synthesis* **1992**, 503 and references cited therein; (b) For applications, see: Bao, J.; Wulff, W. D.; Dominy, J. B.; Fumo, M. J.; Grant, E. B.; Rob, A. C.; Whitcomb, M. C.; Yeung, S.-M.; Ostrander, R. L.; Rheingold, A. L. *J*. *Am*. *Chem*. *Soc*. **1996**, 118, 3392 and references cited therein.
- 2. (a) Cai, D.; Payack, J. F.; Verhoeven, T. R. US Patent 5,399,771; (b) Cai, D.; Payack, J. F.; Bender, D. R.; Hughes, D. L.; Verhoeven, T. R.; Reider, P. J. *J*. *Org*. *Chem*. **1994**, 59, 7180 and references cited therein.
- 3. Enev, V.; Ewers, Ch. L. J.; Harre, M.; Nickisch, K.; Mohr, J. T. *J*. *Org*. *Chem*. **1997**, 62, 7092.
- 4. Enev, V.; Harre, M.; Nickisch, K.; Schneider, M.; Mohr, J. *Tetrahedron*: *Asymmetry* **2000**, 11, 1767–1779 and references cited therein.
- 5. All new compounds have been unambigously characterized by NMR  $(^1H$  and  $^{13}C$ ), IR and MS (high resolution).
- 6. Kabalka, G. W.; Maddox, J. T.; Bogas, E.; Kelley, S. W. *J*. *Org*. *Chem*. **1997**, 62, 3688–3695 and references cited therein.
- 7. Schering procedure.
- 8. Ihara, M.; Suzuki, T.; Katogi, M.; Taniguchi, N.; Fukumoto, K. *J*. *Chem*. *Soc*., *Perkin Trans*. 1 **1992**, 865–873.
- 9. Kluge, A. F.; Maddox, M. L.; Partridge, L. G. *J*. *Org*. *Chem*. **1985**, 50, 2359–2365.
- 10. Kostova, K.; Genov, M.; Philipova, I.; Dimitrov, V. *Tetrahedron*: *Asymmetry* **2000**, 11, 3253–3256.
- 11. Hodgson, D. M.; Stupple, P. A.; Pierard, F. Y. T. M.; Labande, A. H.; Johnstone, C. *Chem*. *Eur*. *J*. **2001**, <sup>7</sup>, 4465–4476.